JOSEPH C. BOTTINO, M.D.; CHARLES K. TASHIMA, M.D.
To the editor: Sutton and associates (1) observed one patient with a family history of diabetes mellitus who developed irreversible insulin-dependent diabetes after 1 year of, therapy with medroxyprogesterone acetate. They attributed this isolated event to a chance occurrence, noting the absence of evidence that progestational agents adversely affect carbohydrate metabolism. The case described below suggests that the appearance of overt diabetes in their patient may not have been simply coincidental with progestational therapy.
Our patient is a 51-year-old white woman who underwent a left radical mastectomy and prophylactic oophorectomy for carcinoma of the breast in 1963. She was referred
Learn more about subscription options.
Register Now for a free account.
BOTTINO JC, TASHIMA CK. Medroxyprogesterone Acetate and Diabetes Mellitus. Ann Intern Med. 1976;84:341–342. doi: 10.7326/0003-4819-84-3-341
Download citation file:
Published: Ann Intern Med. 1976;84(3):341-342.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only